uniQure N.V. (QURE)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Matthew Craig Kapusta | CEO & Executive Director | 1.02M | -- | 1972 |
| Mr. Christian Klemt | CFO, Principal Financial Officer & GM of Amsterdam Site | 575.46k | -- | 1973 |
| Mr. Richard Porter Ph.D. | Chief Business & Scientific Officer | 732.17k | -- | 1968 |
| Dr. Jeannette Potts J.D., Ph.D. | Chief Legal & Compliance Officer and Corporate Secretary | 635.56k | -- | 1962 |
| Prof. Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | -- | -- | -- |
| Dr. Amin Abujoub Ph.D. | Chief Technical Operations | -- | -- | -- |
| Dr. Tamara Tugal Ph.D., MBA | Business Development Director | -- | -- | -- |
| Ms. Erin Boyer | Chief People & Culture Officer | -- | -- | -- |
| Ms. Maria E. Cantor | Chief Corporate Affairs Officer | 491.12k | -- | 1968 |
| Dr. Walid Abi-Saab M.D. | Chief Medical Officer | -- | -- | 1965 |
uniQure N.V.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 480
Description
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Corporate Governance
Upcoming Events
August 1, 2024 at 11:05 AM UTC
uniQure N.V. Earnings Date